Alnylam Pharmaceuticals, Inc. Stock price
Equities
ALNY
US02043Q1076
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
147.4 USD | -1.25% | -1.13% | -22.99% |
Financials (USD)
Sales 2024 * | 1.84B | Sales 2025 * | 2.26B | Capitalization | 18.57B |
---|---|---|---|---|---|
Net income 2024 * | -524M | Net income 2025 * | -245M | EV / Sales 2024 * | 9.92 x |
Net cash position 2024 * | 340M | Net cash position 2025 * | 563M | EV / Sales 2025 * | 7.96 x |
P/E ratio 2024 * |
-35.3
x | P/E ratio 2025 * |
-84.3
x | Employees | 2,100 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.3% |
Latest transcript on Alnylam Pharmaceuticals, Inc.
1 day | -1.25% | ||
1 week | -1.13% | ||
Current month | -2.44% | ||
1 month | +0.28% | ||
3 months | -20.85% | ||
6 months | -18.00% | ||
Current year | -22.99% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 61 | 16-09-18 | |
Jeffrey Poulton
DFI | Director of Finance/CFO | 56 | 19-08-12 |
Piyush Sharma
CMP | Compliance Officer | - | 22-09-20 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Pyott
BRD | Director/Board Member | 71 | 15-12-17 |
Charles Sigal
BRD | Director/Board Member | 72 | 22-08-21 |
Margaret Hamburg
BRD | Director/Board Member | 68 | 19-01-09 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
5.08% | 1 M€ | -.--% | - | |
4.04% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-18 | 147.4 | -1.25% | 460,718 |
24-03-15 | 149.3 | +0.50% | 906,206 |
24-03-14 | 148.5 | +0.07% | 505,848 |
24-03-13 | 148.4 | +1.21% | 858,993 |
24-03-12 | 146.6 | -1.64% | 683,597 |
Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.99% | 18.57B | |
+9.72% | 46.21B | |
+35.14% | 40.04B | |
+4.84% | 39.92B | |
-9.43% | 28.33B | |
+17.47% | 27.43B | |
+10.88% | 13.46B | |
+27.53% | 12.02B | |
-6.84% | 11.3B | |
+6.40% | 11.01B |